Shunt infections: prevention and treatment.
D000583:Amikacin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D002557:Cerebrospinal Fluid Shunts / Q000009:adverse effects*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000209:etiology / Q000628:therapy; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D007710:Klebsiella Infections / Q000209:etiology / Q000628:therapy; D007962:Leukocytes / Q000502:physiology; D008581:Meningitis / Q000209:etiology / Q000628:therapy; D011292:Premedication; D011552:Pseudomonas Infections / Q000209:etiology / Q000628:therapy; D012086:Reoperation; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000209:etiology / Q000628:therapy; D013212:Staphylococcus epidermidis; D014031:Tobramycin / Q000627:therapeutic use; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D014640:Vancomycin; D000583:Amikacin; D012293:Rifampin; D014031:Tobramycin